Comparing 3 approaches for advanced solid tumor

Exclusion

• −Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products or other monoclonal antibodies
• −Has active or uncontrolled human immunodeficiency virus (HIV) infection as determined by plasma HIV ribonucleic acid (RNA) viral load and CD4 count.
• −Has active or uncontrolled HBV or HCV. Hepatitis B and C screeningScreeningThe checks done before joining, to see whether a study fits.Read more → testing is required. Participants are eligible only if they meet criteria as specified in the protocolProtocolThe detailed plan a study must follow.Read more →.
• −Has had prior treatment with an anti-CD47 or anti-signal regulatory protein α (SIRPα) therapy.
• −Has an inadequate treatment washout periodWashout periodA gap with no treatment, so the previous one clears your system.Read more → prior to start of study treatment as specified in the protocol
• −Medical history of myocardial infarction (MI) within 6 months before study enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →, symptomatic congestive heart failure (CHF) (New York Heart Association \[NYHA\] Class II to IV
• −Has a QT interval corrected with Fridericia's formula (QTcF) prolongation to \>470 ms (females) or \>450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram (ECG)
• −Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
• −Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to controlControl groupThe group a new treatment is measured against.Read more → associated symptoms
• −Has multiple primary malignancies within 3 years. Exceptions are specified in the protocol.
• −Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
• −Is requiring concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications during the study
• −Has received a live, attenuated vaccine (messenger ribonucleic acid \[mRNA\] and replication-deficient adenoviral vaccines are not considered live, attenuated vaccines) within 30 days prior to first exposure to study drug(s)
• −Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →, interfere with the participant's participation in the clinical study or evaluation of the clinical study results.
• −Has unresolved toxicities from previous anticancer therapy
• −Has lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder
• −Any autoimmune, connective tissue or inflammatory disorders
• −Prior complete pneumonectomy
• −Any of the following within 6 months of enrollment: Cerebrovascular accident, transient ischemic attack, or other arterial thromboembolism event
• −Psychological, social, familial, or geographical factors that would prevent regular follow-upFollow-upContinued check-ins after the treatment part is finished.Read more →
• −Any active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy
• −Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) and/or severe arrhythmia within 28 days before enrollment
• −Female who is pregnant, breastfeeding, or planning to become pregnant